knowledge -WSS

knowledge

author：leisure time 2025-09-30 19:26:32 - browse：94

Fran van Delft for Galapagos

Seeking to differentiate itself from other makers of CAR-T cancer therapies, Galapagos NV on Wednesday announced it had struck a deal with Blood Centers of America to open up dozens of manufacturing sites for its cell-based medicines around the U.S.

Galapagos said it will rely on the partnership, the financial terms of which were not disclosed, as it moves its CAR-Ts for different cancers into pivotal studies and could also help launch those medicines should they win approval. The Belgian company framed the collaboration as one that could help overcome the limitations that have held back access to existing CAR-T therapies from other companies.

CAR-Ts have proven to be potent treatments for certain cancers, but they are complicated medicines to make. Immune cells have to be removed from a patient, shipped to specialty sites, where they’re engineered with cancer-killing abilities, and then returned to the hospital for infusion back into patients. The process, which can take weeks if not months, has put a crunch on the number of patients companies and hospitals are able to treat.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Gritstone Bio's cancer vaccine test, and more on Novartis' deal

WSS

Readout Newsletter: Amgen, Regeneron, BGI Group and more

Padmanee Sharma of MD Anderson at center of lawsuit over credit

States increasingly look to regulate hospital facility fees

Why Novartis is going to walk from its acquisition of MorphoSys

Suspected Gilgo Beach killer appeared 'traumatized' after arrest: Defense attorney

Johnson & Johnson sued for allegedly overpaying for workers' drugs

explore

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Dobbs anniversary: the lost opportunity of abortion as health care

Couple fighting to bring baby home from Mexico are finally reunited

Bright Health sells Medicare Advantage business to Molina

Bernie brings in new pharma CEOs to talk drug prices

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

How dance can help health care workers heal from trauma

BioMarin wins approval for gene therapy to treat hemophilia A

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Bright Health sells Medicare Advantage business to Molina

AI gets buy

leisure time

The kidney, in all its complexity, is captured in a new atlas

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

Stanford updates investigation of president’s past research

Adopting new red light myopia treatments may be short

Why the Crimean Bridge is key to Russia's war in Ukraine

A single Democrat is willing to weaken Medicare negotiation power

leisure time

entertainment

focus

focus